Metoclopramide is one of those “small drug, big board presence” meds: it shows up in GI pharmacology, OB, neuro side effects, and endocrine-style questions (galactorrhea/amenorrhea). If you can quickly recognize when to use it and what toxicity looks like, you’ll grab a lot of easy points on Step 1—and avoid common distractors like erythromycin, ondansetron, and anticholinergics.
Where Metoclopramide Fits in GI Pharm (Step 1 framing)
Metoclopramide is primarily a prokinetic and antiemetic.
You’ll see it used for:
- Gastroparesis (especially diabetic gastroparesis)
- GERD (as a motility agent when lifestyle/acid suppression isn’t enough)
- Antiemetic settings (eg, postoperative nausea; migraine-associated nausea; sometimes chemotherapy—though 5-HT3 antagonists are more classic)
First Aid cross-reference (conceptual): GI pharmacology → Antiemetics/Prokinetics; dopamine antagonists and extrapyramidal side effects; hyperprolactinemia.
Definition (one-liner you can memorize)
Metoclopramide = D2 receptor antagonist (also 5-HT4 agonist) that increases GI motility and acts as an antiemetic by blocking dopamine signaling in the chemoreceptor trigger zone.
Mechanism of Action (HY and testable)
Primary MOA (what they expect you to say)
- D2 antagonism
- CNS: blocks dopamine receptors in the CTZ (area postrema) → antiemetic
- GI tract: reduces inhibitory dopaminergic tone on enteric cholinergic neurons → increases ACh release → prokinetic effect
Additional serotonergic effects (often tested as “also does this”)
- 5-HT4 agonist → enhances enteric neurotransmission → increases peristalsis
- (Less emphasized but sometimes mentioned) 5-HT3 antagonism at higher doses → antiemetic contribution
Net physiologic effects (know these)
Metoclopramide:
- Increases LES tone → helps GERD
- Increases gastric emptying → helps gastroparesis
- Increases small intestinal transit
- Has less effect on colonic motility than on upper GI (don’t overstate “helps constipation” unless the question cues it)
Pathophysiology: Why it helps in diabetic gastroparesis
Diabetic gastroparesis is largely due to autonomic (vagal) neuropathy and impaired enteric neuronal function, leading to:
- Delayed gastric emptying
- Early satiety, nausea, vomiting
- Poor glycemic control (food absorption becomes unpredictable)
Metoclopramide helps by pushing the stomach forward—increasing coordinated contractions and promoting gastric emptying.
Clinical Presentation: When the vignette is screaming “use metoclopramide”
Gastroparesis vignette clues
- Long-standing diabetes (or post-surgical vagal injury)
- Postprandial nausea/vomiting
- Early satiety, bloating
- Abdominal discomfort
- Symptoms worse after meals
- Erratic glucose control due to delayed emptying
GERD vignette clues (less common Step 1 use-case)
- Heartburn/regurgitation symptoms + evidence of low LES tone
- Patient already on acid suppression, still symptomatic, motility angle emphasized
Nausea/vomiting vignette clues
- Post-op nausea
- Migraine with prominent nausea
- “Antiemetic that can cause dystonia” is often metoclopramide (or prochlorperazine)
Diagnosis (what tests are associated with the conditions it treats)
Metoclopramide itself isn’t “diagnosed,” but you should recognize the typical workup for gastroparesis.
Gastroparesis evaluation (common board logic)
- Rule out mechanical obstruction
- Typically with upper endoscopy or imaging if alarm features
- Confirm delayed emptying
- Gastric emptying scintigraphy (classic test)
Boards love to test: don’t call it gastroparesis until obstruction is excluded.
Treatment: Where metoclopramide sits in management
Diabetic gastroparesis (high-yield sequence)
- Dietary modifications: small frequent meals, low fat, low fiber
- Optimize glucose control
- Prokinetics:
- Metoclopramide (key Step drug)
- Erythromycin (motilin receptor agonist) as an alternative/adjunct
- Antiemetics for symptom control if needed
GERD (as a “motility adjunct”)
- Lifestyle + PPIs/H2 blockers first-line
- Metoclopramide is not first-line for routine GERD, but may appear when the question highlights motility/LES tone.
Adverse Effects: The exam loves the toxicity more than the benefits
1) Extrapyramidal symptoms (EPS) — classic Step trap
Due to central D2 blockade:
- Acute dystonia (hours–days): torticollis, oculogyric crisis
- Akathisia: inner restlessness
- Parkinsonism: bradykinesia, rigidity, tremor
- Tardive dyskinesia (months): choreoathetoid movements, lip smacking
Treatment of acute dystonia/EPS (high-yield pairing):
- Benztropine (anticholinergic) or diphenhydramine
Big warning: Metoclopramide has a known association with tardive dyskinesia, especially with prolonged use—this is why long-term therapy is avoided.
2) Hyperprolactinemia
Dopamine normally inhibits prolactin. Blocking D2 → ↑ prolactin:
- Galactorrhea
- Amenorrhea
- Gynecomastia
- Sexual dysfunction
This is a favorite “GI drug causing endocrine symptoms” crossover.
3) Neuroleptic malignant syndrome (rare but board-relevant)
Any dopamine antagonist can do this:
- Fever, rigidity (“lead pipe”), autonomic instability, altered mental status
- ↑ CK
- Treated with dantrolene and/or bromocriptine (depending on framing)
4) Diarrhea/cramping
From increased motility.
5) QT prolongation?
Not the signature toxicity for metoclopramide on Step 1 compared with agents like ondansetron, but if a question stem is pushing QT issues, consider alternatives first (e.g., 5-HT3 antagonists).
Contraindications & Cautions (quick hitters)
Think: “If you push motility in the wrong situation, you can make things worse.”
- Mechanical bowel obstruction: increasing peristalsis against an obstruction = bad idea
- Parkinson disease: D2 blockade can worsen symptoms
- History of tardive dyskinesia/EPS
- Pheochromocytoma (rarely emphasized): dopamine antagonism can precipitate catecholamine release → hypertension (occasionally tested)
High-Yield Associations & Classic Question Stems
Association table (Step 1 favorites)
| Clue in the stem | What it’s pointing to | Why |
|---|---|---|
| Diabetic patient with early satiety + postprandial vomiting | Gastroparesis → metoclopramide | Prokinetic increases gastric emptying |
| New-onset involuntary facial movements after chronic use | Tardive dyskinesia | Chronic D2 blockade |
| Acute torticollis/oculogyric crisis after an antiemetic | Acute dystonia | D2 antagonists (metoclopramide, prochlorperazine) |
| Galactorrhea + amenorrhea after “GI med” | Hyperprolactinemia | Dopamine normally inhibits prolactin |
| “CTZ blockade” antiemetic with EPS | Metoclopramide | D2 blockade in area postrema |
Metoclopramide vs. similar drugs (don’t get baited)
| Drug | Main MOA | Big use | Signature toxicity |
|---|---|---|---|
| Metoclopramide | D2 antagonist; 5-HT4 agonist | Gastroparesis, antiemetic | EPS, hyperprolactinemia, tardive dyskinesia |
| Ondansetron | 5-HT3 antagonist | Chemo/post-op nausea | QT prolongation, constipation, headache |
| Erythromycin | Motilin receptor agonist | Gastroparesis (alt) | QT prolongation, GI upset |
| Scopolamine | Antimuscarinic | Motion sickness | Anticholinergic effects |
| Prochlorperazine | D2 antagonist | Antiemetic | EPS, hyperprolactinemia |
First Aid-Style Memory Hooks (no fluff, just useful)
- “Metoclopramide moves the stomach.”
Prokinetic for gastroparesis. - “D2 block = dystonia + prolactin.”
Think EPS and galactorrhea/amenorrhea. - If the stem mentions area postrema / CTZ + EPS, metoclopramide should pop into your head.
Rapid Review (what you should be able to say in 10 seconds)
- Metoclopramide: D2 antagonist, 5-HT4 agonist → prokinetic + antiemetic
- Uses: diabetic gastroparesis, GERD adjunct, nausea/vomiting
- Toxicity: EPS (acute dystonia, tardive dyskinesia), hyperprolactinemia, rare NMS
- Avoid in obstruction; caution in Parkinson disease